Ethical perspectives on RNA interference therapeutics
Ebbesen M, Jensen TG, Andersen S, Pedersen FS.
Centre for Bioethics, Nanoethics,
University of Aarhus, Denmark.
Int J Med Sci. 2008 Jun 25;5(3):159-68.
ABSTRACTRNA interference is a mechanism for controlling normal gene expression which has recently begun to be employed as a potential therapeutic agent for a wide range of disorders, including cancer, infectious diseases and metabolic disorders. Clinical trials with RNA interference have begun. However, challenges such as off-target effects, toxicity and safe delivery methods have to be overcome before RNA interference can be considered as a conventional drug. So, if RNA interference is to be used therapeutically, we should perform a risk-benefit analysis. It is ethically relevant to perform a risk-benefit analysis since ethical obligations about not inflicting harm and promoting good are generally accepted. But the ethical issues in RNA interference therapeutics not only include a risk-benefit analysis, but also considerations about respecting the autonomy of the patient and considerations about justice with regard to the inclusion criteria for participation in clinical trials and health care allocation. RNA interference is considered a new and promising therapeutic approach, but the ethical issues of this method have not been greatly discussed, so this article analyses these issues using the bioethical theory of principles of the American bioethicists, Tom L. Beauchamp and James F. Childress.Eugenics
'Liberal eugenics' (PDF)
Germline genetic engineering
Congenital insensitivity to pain
Artificial insemination and eugenics
Gene therapy and performance enhancement
An overview of Autism and Asperger syndrome
Transhumanism (H+): toward a Brave New World?
and further reading
The Good Drug Guide
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
MDMA: Utopian Pharmacology
Critique of Huxley's Brave New World